Web excl: Brian Tempest encouraged Malvinder

Bs_logoImage
Tinesh Bhasin Mumbai
Last Updated : Jan 20 2013 | 9:23 PM IST

New Delhi-based Ranbaxy's founders Malvinder Singh and his family sold their 34.82 per cent stake in the company to Daiichi Sankyo for as much as $4.6 billion.

Tempest joined the company in 1995, as regional director, Europe, CIS and Africa, and in 2000 was promoted to become president - pharmaceuticals worldwide. In 2003, the board appointed him as joint managing director and CEO designate, and in 2004 he took over as CEO and managing director of the Company. In 2006, he was appointed as chief mentor and executive vice chairman, a position he held till December 2007. He is currently a non-executive director of the company. Tempest spoke to Business Standard from London in a phone interview on the sell-out by Ranbaxy founders to Japanese multinational Daiichi Sankyo.

Do you think it was necessary for Malvinder Singh to sell Ranbaxy?

I have been encouraging Malvinder Singh for this deal. If you look at this deal from the Indian company's perspective, you will think ownership is important for a company's growth. But the global scenario is different in the pharmaceutical space. One should realise most of the CEOs of the large international pharmaceutical companies don't hold any stake in the company they manage and are only true professionals.

Why did you encourage Malvinder Singh to sell the business at this stage, when the company was turning around?

Ranbaxy is already the largest domestic pharmaceutical company and this is continuation of building itself into a global company and taking it to the next level of growth.

How does Daiichi Sankyo benefit from the deal?

Japanese companies have pressure to focus on the generics business due to governmental regulations. This is why, increasingly Japaneses firms are looking to partner Indian companies.

How will this deal impact the Indian pharmaceutical space?

A lot of global companies want to leverage India advantage of low-cost and skilled manpower. International players are looking at alliances as the cost of manufacturing is on rise in that part of the world.

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 13 2008 | 4:49 PM IST